Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics Q3 net loss widens to $27.2 million from $14.3 million

Negative Impact 3 of 5 earnings

Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.

Key points

  • Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
  • Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
  • Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.

The filing

CompanyCompass Therapeutics, Inc. (CMPX)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:00 AM ET
Accession number0001171843-26-007256

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:25 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.